<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01823328</url>
  </required_header>
  <id_info>
    <org_study_id>HSR 13-3601</org_study_id>
    <nct_id>NCT01823328</nct_id>
  </id_info>
  <brief_title>Ketamine Versus Etomidate for Rapid Sequence Intubation</brief_title>
  <official_title>Ketamine Versus Etomidate for Sedation of Emergency Department Patients During Rapid Sequence Intubation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hennepin Healthcare Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hennepin Healthcare Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effectiveness and safety of ketamine and
      etomidate during rapid sequence intubation (RSI).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized controlled trial of etomidate versus ketamine during rapid
      sequence intubation (RSI). RSI refers to the process by which patients who require emergency
      airway management undergo sedation and paralysis prior to insertion of an endotracheal
      tube(airway tube). Patients who require intubation will be randomized to have intubation
      performed with either ketamine or etomidate. All other care will be at the discretion of the
      treating physicians. The purpose of this study is to compare the efficacy and safety of
      ketamine and etomidate during rapid sequence intubation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SOFA Score</measure>
    <time_frame>up to 3 days</time_frame>
    <description>*Maximum SOFA score within three hospital days: all patients. SOFA score is the Sequential Organ Failure Assessment. The minimum score is 0, the maximum score is 24, with higher scores indicating higher likelihood of worse outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality in Sepsis and Septic Shock</measure>
    <time_frame>30 Days</time_frame>
    <description>Evaluate mortality for the sub-group diagnosed with sepsis and septic shock, defined as:
- Suspected infection, and at least 2 of 4 systemic inflammatory response syndrome (SIRS) criteria:
Temperature &gt;38C or &lt;36C
Respiratory Rate &gt;20 or PaCO2 &lt;32 mmHg
Heart Rate &gt;90
White blood cell count &gt;12,000 or &lt;4,000, or &gt; 10% bands
Septic shock:
defined as sepsis plus either: 1) Systolic blood pressure &lt;90 after 1L of intravenous fluid or 2) lactate &gt;=4mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With First-pass Success</measure>
    <time_frame>up to 5 minutes (average time frame)</time_frame>
    <description>The rate of first pass success, defined as successful tracheal intubation on the first attempt. An attempt is defined as the insertion and subsequent removal of the laryngoscopic device from the patient's mouth, regardless of whether an endotracheal tube was inserted.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Doses of Post-intubation Sedation</measure>
    <time_frame>up to 6 hours</time_frame>
    <description>The number of bolus doses of sedative administered post-intubation will be compared up to 6 hours (including morphine, dexmedetomidine, propofol , etomidate, ketamine, lorazepam (Ativan), midazolam (Versed), diazepam (Valium), fentanyl, hydromorphone (Dilaudid)). Infusions of these medications will be recorded separately but will not be part of this outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Post-intubation Hypoxemia</measure>
    <time_frame>up to 2 hours</time_frame>
    <description>The following will be compared between the two groups:
Hypoxemia and severe hypoxemia in the peri-intubation period. Peri-intubation hypoxemia was defined as during after the 5 minutes immediately after intubation.
Hypoxemia within the first 2 hours intubation
Hypoxemia is defined as SpO2 less than 90%. Severe hypoxemia is defined as SpO2 less than 90% for 60 seconds or more.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Hypotension</measure>
    <time_frame>up to 6 hours</time_frame>
    <description>The following will be compared between the two groups:
Hypotension in the ED post-intubation
Hypotension within the first 6 hours of the hospital stay, including time spent in the ED
Hypotension is defined as a systolic blood pressure less than 90 mm Hg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak and Plateau Pressure</measure>
    <time_frame>up to 30 minutes (average time frame)</time_frame>
    <description>The Peak and plateau pressures will be compared between the two groups, with a pre-defined subgroup analysis of patients who are being intubated for severe asthma and chronic obstructive pulmonary disease (COPD). The ventilator was used to measure these values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>30 Days or Discharge</time_frame>
    <description>Mortality will be assessed at 30 days or at discharge from the hospital, whichever occurs first. This study is not powered to detect a significant difference in mortality, however; this will primarily be a safety study comparing the use ketamine versus etomidate as sedative agents for rapid sequence intubation (RSI) in the Emergency Department (ED).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">143</enrollment>
  <condition>Airway Control</condition>
  <condition>Anesthesia</condition>
  <condition>Intubation</condition>
  <condition>Complication</condition>
  <arm_group>
    <arm_group_label>Ketamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects in the ketamine arm will receive ketamine for sedation prior to rapid sequence intubation (RSI).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Etomidate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects in the etomidate arm will receive etomidate for sedation prior to rapid sequence intubation (RSI).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>Subjects will receive ketamine for sedation prior to rapid sequence intubation.</description>
    <arm_group_label>Ketamine</arm_group_label>
    <other_name>Ketanest</other_name>
    <other_name>Ketaset</other_name>
    <other_name>Ketalar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etomidate</intervention_name>
    <description>Subjects will receive etomidate for sedation prior to rapid sequence intubation.</description>
    <arm_group_label>Etomidate</arm_group_label>
    <other_name>Amidate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age

          -  Undergoing rapid sequence intubation (RSI) in the Emergency Department

        Exclusion Criteria:

          -  Known contraindication to ketamine or etomidate

          -  Patient has a condition in which an increase in heart rate or blood pressure would be
             hazardous, as judged by the treating physician

          -  Patient is known or suspected of having increased intracranial pressure, based on the
             history and physical examination performed by the treating physician.

          -  Females of child-bearing age, defined as 18-50 years, who do not have a documented
             pregnancy test in this institution confirming that they are not pregnant or who do not
             have a confirmed surgical procedure preventing pregnancy, i.e., tubal ligation,
             hysterectomy. The timing of the pregnancy test at which the investigative team will
             consider a subject to be non-pregnant is a documented negative test during current
             hospitalization or upon direct transfer from outside institution during current
             illness.

          -  Patient declines participation in the trial by wearing a bracelet marked &quot;KvE
             declined&quot;

          -  Prisoner
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian E Driver, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hennepin County Medical Canter</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hennepin County Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55415</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>March 28, 2013</study_first_submitted>
  <study_first_submitted_qc>April 2, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2013</study_first_posted>
  <results_first_submitted>August 29, 2018</results_first_submitted>
  <results_first_submitted_qc>May 2, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 24, 2019</results_first_posted>
  <last_update_submitted>May 2, 2019</last_update_submitted>
  <last_update_submitted_qc>May 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intubation</keyword>
  <keyword>Airway</keyword>
  <keyword>Emergent intubation</keyword>
  <keyword>Rapid sequence intubation</keyword>
  <keyword>Rapid sequence induction</keyword>
  <keyword>RSI</keyword>
  <keyword>Ketamine</keyword>
  <keyword>Etomidate</keyword>
  <keyword>Sepsis</keyword>
  <keyword>Sedative</keyword>
  <keyword>Sedation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Etomidate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>14 patients withdrew consent.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ketamine</title>
          <description>Subjects in the ketamine arm will receive ketamine for sedation prior to rapid sequence intubation (RSI).
Ketamine: Subjects will receive ketamine for sedation prior to rapid sequence intubation.</description>
        </group>
        <group group_id="P2">
          <title>Etomidate</title>
          <description>Subjects in the etomidate arm will receive etomidate for sedation prior to rapid sequence intubation (RSI).
Etomidate: Subjects will receive etomidate for sedation prior to rapid sequence intubation.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="73"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
                <participants group_id="P2" count="67"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ketamine</title>
          <description>Subjects in the ketamine arm will receive ketamine for sedation prior to rapid sequence intubation (RSI).
Ketamine: Subjects will receive ketamine for sedation prior to rapid sequence intubation.</description>
        </group>
        <group group_id="B2">
          <title>Etomidate</title>
          <description>Subjects in the etomidate arm will receive etomidate for sedation prior to rapid sequence intubation (RSI).
Etomidate: Subjects will receive etomidate for sedation prior to rapid sequence intubation.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="62"/>
            <count group_id="B2" value="67"/>
            <count group_id="B3" value="129"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49" spread="20"/>
                    <measurement group_id="B2" value="49" spread="19"/>
                    <measurement group_id="B3" value="49" spread="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="75"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>SOFA Score</title>
        <description>*Maximum SOFA score within three hospital days: all patients. SOFA score is the Sequential Organ Failure Assessment. The minimum score is 0, the maximum score is 24, with higher scores indicating higher likelihood of worse outcome.</description>
        <time_frame>up to 3 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine</title>
            <description>Subjects in the ketamine arm will receive ketamine for sedation prior to rapid sequence intubation (RSI).
Ketamine: Subjects will receive ketamine for sedation prior to rapid sequence intubation.</description>
          </group>
          <group group_id="O2">
            <title>Etomidate</title>
            <description>Subjects in the etomidate arm will receive etomidate for sedation prior to rapid sequence intubation (RSI).
Etomidate: Subjects will receive etomidate for sedation prior to rapid sequence intubation.</description>
          </group>
        </group_list>
        <measure>
          <title>SOFA Score</title>
          <description>*Maximum SOFA score within three hospital days: all patients. SOFA score is the Sequential Organ Failure Assessment. The minimum score is 0, the maximum score is 24, with higher scores indicating higher likelihood of worse outcome.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" lower_limit="5" upper_limit="9"/>
                    <measurement group_id="O2" value="7" lower_limit="5" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mortality in Sepsis and Septic Shock</title>
        <description>Evaluate mortality for the sub-group diagnosed with sepsis and septic shock, defined as:
- Suspected infection, and at least 2 of 4 systemic inflammatory response syndrome (SIRS) criteria:
Temperature &gt;38C or &lt;36C
Respiratory Rate &gt;20 or PaCO2 &lt;32 mmHg
Heart Rate &gt;90
White blood cell count &gt;12,000 or &lt;4,000, or &gt; 10% bands
Septic shock:
defined as sepsis plus either: 1) Systolic blood pressure &lt;90 after 1L of intravenous fluid or 2) lactate &gt;=4mmol/L</description>
        <time_frame>30 Days</time_frame>
        <population>Subgroup of those with sepsis</population>
        <group_list>
          <group group_id="O1">
            <title>Ketamine</title>
            <description>Subjects in the ketamine arm will receive ketamine for sedation prior to rapid sequence intubation (RSI).
Ketamine: Subjects will receive ketamine for sedation prior to rapid sequence intubation.</description>
          </group>
          <group group_id="O2">
            <title>Etomidate</title>
            <description>Subjects in the etomidate arm will receive etomidate for sedation prior to rapid sequence intubation (RSI).
Etomidate: Subjects will receive etomidate for sedation prior to rapid sequence intubation.</description>
          </group>
        </group_list>
        <measure>
          <title>Mortality in Sepsis and Septic Shock</title>
          <description>Evaluate mortality for the sub-group diagnosed with sepsis and septic shock, defined as:
- Suspected infection, and at least 2 of 4 systemic inflammatory response syndrome (SIRS) criteria:
Temperature &gt;38C or &lt;36C
Respiratory Rate &gt;20 or PaCO2 &lt;32 mmHg
Heart Rate &gt;90
White blood cell count &gt;12,000 or &lt;4,000, or &gt; 10% bands
Septic shock:
defined as sepsis plus either: 1) Systolic blood pressure &lt;90 after 1L of intravenous fluid or 2) lactate &gt;=4mmol/L</description>
          <population>Subgroup of those with sepsis</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With First-pass Success</title>
        <description>The rate of first pass success, defined as successful tracheal intubation on the first attempt. An attempt is defined as the insertion and subsequent removal of the laryngoscopic device from the patient's mouth, regardless of whether an endotracheal tube was inserted.</description>
        <time_frame>up to 5 minutes (average time frame)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine</title>
            <description>Subjects in the ketamine arm will receive ketamine for sedation prior to rapid sequence intubation (RSI).
Ketamine: Subjects will receive ketamine for sedation prior to rapid sequence intubation.</description>
          </group>
          <group group_id="O2">
            <title>Etomidate</title>
            <description>Subjects in the etomidate arm will receive etomidate for sedation prior to rapid sequence intubation (RSI).
Etomidate: Subjects will receive etomidate for sedation prior to rapid sequence intubation.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With First-pass Success</title>
          <description>The rate of first pass success, defined as successful tracheal intubation on the first attempt. An attempt is defined as the insertion and subsequent removal of the laryngoscopic device from the patient's mouth, regardless of whether an endotracheal tube was inserted.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Doses of Post-intubation Sedation</title>
        <description>The number of bolus doses of sedative administered post-intubation will be compared up to 6 hours (including morphine, dexmedetomidine, propofol , etomidate, ketamine, lorazepam (Ativan), midazolam (Versed), diazepam (Valium), fentanyl, hydromorphone (Dilaudid)). Infusions of these medications will be recorded separately but will not be part of this outcome.</description>
        <time_frame>up to 6 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine</title>
            <description>Subjects in the ketamine arm will receive ketamine for sedation prior to rapid sequence intubation (RSI).
Ketamine: Subjects will receive ketamine for sedation prior to rapid sequence intubation.</description>
          </group>
          <group group_id="O2">
            <title>Etomidate</title>
            <description>Subjects in the etomidate arm will receive etomidate for sedation prior to rapid sequence intubation (RSI).
Etomidate: Subjects will receive etomidate for sedation prior to rapid sequence intubation.</description>
          </group>
        </group_list>
        <measure>
          <title>Doses of Post-intubation Sedation</title>
          <description>The number of bolus doses of sedative administered post-intubation will be compared up to 6 hours (including morphine, dexmedetomidine, propofol , etomidate, ketamine, lorazepam (Ativan), midazolam (Versed), diazepam (Valium), fentanyl, hydromorphone (Dilaudid)). Infusions of these medications will be recorded separately but will not be part of this outcome.</description>
          <units>bolus doses of sedation</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O2" value="1" lower_limit="0" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Post-intubation Hypoxemia</title>
        <description>The following will be compared between the two groups:
Hypoxemia and severe hypoxemia in the peri-intubation period. Peri-intubation hypoxemia was defined as during after the 5 minutes immediately after intubation.
Hypoxemia within the first 2 hours intubation
Hypoxemia is defined as SpO2 less than 90%. Severe hypoxemia is defined as SpO2 less than 90% for 60 seconds or more.</description>
        <time_frame>up to 2 hours</time_frame>
        <population>Those with oxygen saturation data</population>
        <group_list>
          <group group_id="O1">
            <title>Ketamine</title>
            <description>Subjects in the ketamine arm will receive ketamine for sedation prior to rapid sequence intubation (RSI).
Ketamine: Subjects will receive ketamine for sedation prior to rapid sequence intubation.</description>
          </group>
          <group group_id="O2">
            <title>Etomidate</title>
            <description>Subjects in the etomidate arm will receive etomidate for sedation prior to rapid sequence intubation (RSI).
Etomidate: Subjects will receive etomidate for sedation prior to rapid sequence intubation.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Post-intubation Hypoxemia</title>
          <description>The following will be compared between the two groups:
Hypoxemia and severe hypoxemia in the peri-intubation period. Peri-intubation hypoxemia was defined as during after the 5 minutes immediately after intubation.
Hypoxemia within the first 2 hours intubation
Hypoxemia is defined as SpO2 less than 90%. Severe hypoxemia is defined as SpO2 less than 90% for 60 seconds or more.</description>
          <population>Those with oxygen saturation data</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Peri-intubation hypoxemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypoxemia within 2 h of ICU admission</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Hypotension</title>
        <description>The following will be compared between the two groups:
Hypotension in the ED post-intubation
Hypotension within the first 6 hours of the hospital stay, including time spent in the ED
Hypotension is defined as a systolic blood pressure less than 90 mm Hg</description>
        <time_frame>up to 6 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine</title>
            <description>Subjects in the ketamine arm will receive ketamine for sedation prior to rapid sequence intubation (RSI).
Ketamine: Subjects will receive ketamine for sedation prior to rapid sequence intubation.</description>
          </group>
          <group group_id="O2">
            <title>Etomidate</title>
            <description>Subjects in the etomidate arm will receive etomidate for sedation prior to rapid sequence intubation (RSI).
Etomidate: Subjects will receive etomidate for sedation prior to rapid sequence intubation.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Hypotension</title>
          <description>The following will be compared between the two groups:
Hypotension in the ED post-intubation
Hypotension within the first 6 hours of the hospital stay, including time spent in the ED
Hypotension is defined as a systolic blood pressure less than 90 mm Hg</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hypotension in the first 6 hours of hospitalizatio</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypotension in the ED</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak and Plateau Pressure</title>
        <description>The Peak and plateau pressures will be compared between the two groups, with a pre-defined subgroup analysis of patients who are being intubated for severe asthma and chronic obstructive pulmonary disease (COPD). The ventilator was used to measure these values.</description>
        <time_frame>up to 30 minutes (average time frame)</time_frame>
        <population>Those with peak and plateau pressure available</population>
        <group_list>
          <group group_id="O1">
            <title>Ketamine</title>
            <description>Subjects in the ketamine arm will receive ketamine for sedation prior to rapid sequence intubation (RSI).
Ketamine: Subjects will receive ketamine for sedation prior to rapid sequence intubation.</description>
          </group>
          <group group_id="O2">
            <title>Etomidate</title>
            <description>Subjects in the etomidate arm will receive etomidate for sedation prior to rapid sequence intubation (RSI).
Etomidate: Subjects will receive etomidate for sedation prior to rapid sequence intubation.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak and Plateau Pressure</title>
          <description>The Peak and plateau pressures will be compared between the two groups, with a pre-defined subgroup analysis of patients who are being intubated for severe asthma and chronic obstructive pulmonary disease (COPD). The ventilator was used to measure these values.</description>
          <population>Those with peak and plateau pressure available</population>
          <units>cm water</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Peak pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25" lower_limit="23" upper_limit="30"/>
                    <measurement group_id="O2" value="26" lower_limit="22" upper_limit="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plateau Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" lower_limit="14" upper_limit="20"/>
                    <measurement group_id="O2" value="17" lower_limit="16" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mortality</title>
        <description>Mortality will be assessed at 30 days or at discharge from the hospital, whichever occurs first. This study is not powered to detect a significant difference in mortality, however; this will primarily be a safety study comparing the use ketamine versus etomidate as sedative agents for rapid sequence intubation (RSI) in the Emergency Department (ED).</description>
        <time_frame>30 Days or Discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine</title>
            <description>Subjects in the ketamine arm will receive ketamine for sedation prior to rapid sequence intubation (RSI).
Ketamine: Subjects will receive ketamine for sedation prior to rapid sequence intubation.</description>
          </group>
          <group group_id="O2">
            <title>Etomidate</title>
            <description>Subjects in the etomidate arm will receive etomidate for sedation prior to rapid sequence intubation (RSI).
Etomidate: Subjects will receive etomidate for sedation prior to rapid sequence intubation.</description>
          </group>
        </group_list>
        <measure>
          <title>Mortality</title>
          <description>Mortality will be assessed at 30 days or at discharge from the hospital, whichever occurs first. This study is not powered to detect a significant difference in mortality, however; this will primarily be a safety study comparing the use ketamine versus etomidate as sedative agents for rapid sequence intubation (RSI) in the Emergency Department (ED).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ketamine</title>
          <description>Subjects in the ketamine arm will receive ketamine for sedation prior to rapid sequence intubation (RSI).
Ketamine: Subjects will receive ketamine for sedation prior to rapid sequence intubation.</description>
        </group>
        <group group_id="E2">
          <title>Etomidate</title>
          <description>Subjects in the etomidate arm will receive etomidate for sedation prior to rapid sequence intubation (RSI).
Etomidate: Subjects will receive etomidate for sedation prior to rapid sequence intubation.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Severe hypertension</sub_title>
                <description>After ketamine administration one patient had severely elevated blood pressure &gt; 200/100 mm Hg</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Audrey Hendrickson</name_or_title>
      <organization>Hennepin Healthcare</organization>
      <phone>612-873-9528</phone>
      <email>Audrey.Hendrickson@hcmed.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

